TY 51469

Drug Profile

TY 51469

Alternative Names: TY-51469

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Toa Eiyo
  • Class Eye disorder therapies
  • Mechanism of Action Chymase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Post-surgical adhesions

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Post-surgical-adhesions in Japan (Ophthalmic, Irrigation)
  • 31 Jan 2008 Preclinical development is ongoing
  • 03 Nov 2003 TY 51469 is available for licensing (http://www.toaeiyo.co.jp/)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top